Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase the risk of intracranial hemorrhage?
The US Food and Drug Administration has issued a warning that tipranavir may be associated with increased risk of intracranial hemorrhage. We studied 2 large cohorts to estimate the background rate of intracranial hemorrhage and compared it with rates reported among persons who had been exposed to tipranavir.
Justice
Amy C
AC
Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut 06516, USA.
Zingmond
David S
DS
Gordon
Kirsha S
KS
Fultz
Shawn L
SL
Goulet
Joseph L
JL
King
Joseph T
JT
Bravata
Dawn M
DM
Valdez
Hernan
H
Kraft
Michael
M
Mattocks
Kristin M
KM
D000328:Adult; D000367:Age Factors; D019380:Anti-HIV Agents / Q000009:adverse effects*; D002140:California / Q000453:epidemiology; D015331:Cohort Studies; D016208:Databases, Factual; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D020300:Intracranial Hemorrhages / Q000453:epidemiology / Q000209:etiology*; D008297:Male; D008484:Medicaid / Q000706:statistics & numerical data; D008875:Middle Aged; D011725:Pyridines / Q000009:adverse effects*; D011753:Pyrones / Q000009:adverse effects*; D012307:Risk Factors; D013449:Sulfonamides; D014481:United States / Q000453:epidemiology; D014728:Veterans / Q000706:statistics & numerical data
D019380:Anti-HIV Agents; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; C107201:tipranavir